These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21673355)

  • 101. Ask the doctor. I'm 50 years old and have never had an HPV test. Do I need one as part of my health screening?
    Robb-Nicholson C
    Harv Womens Health Watch; 2011 Apr; 18(8):8. PubMed ID: 21544976
    [No Abstract]   [Full Text] [Related]  

  • 102. HPV-based screening for prevention of invasive cervical cancer.
    Schneider A; Petry U; Erdemoglu E; Paavonen J
    Lancet; 2014 Apr; 383(9925):1294-1295. PubMed ID: 24725575
    [No Abstract]   [Full Text] [Related]  

  • 103. HPV-based screening for prevention of invasive cervical cancer.
    Sideri M; Igidbashian S
    Lancet; 2014 Apr; 383(9925):1294. PubMed ID: 24725574
    [No Abstract]   [Full Text] [Related]  

  • 104. HPV-based screening for prevention of invasive cervical cancer - Authors' reply.
    Ronco G; Meijer CJL; Segnan N; Kitchener H; Giorgi-Rossi P; Peto J; Dillner J
    Lancet; 2014 Apr; 383(9925):1295. PubMed ID: 24725577
    [No Abstract]   [Full Text] [Related]  

  • 105. Modelling the impact of population-based cytologic screening on cervical cancer incidence and mortality in Hong Kong: an age--period--cohort approach.
    Woo PP; Thach TQ; Choy ST; McGhee SM; Leung GM
    Br J Cancer; 2005 Oct; 93(9):1077-83. PubMed ID: 16205695
    [TBL] [Abstract][Full Text] [Related]  

  • 106. HPV screening for cervical cancer in rural India.
    Mwanahamuntu MH; Sahasrabuddhe VV; Parham GP
    N Engl J Med; 2009 Jul; 361(3):305; author reply 306. PubMed ID: 19610158
    [No Abstract]   [Full Text] [Related]  

  • 107. Debates about cervical screening: an historical overview.
    Bryder L
    J Epidemiol Community Health; 2008 Apr; 62(4):284-7. PubMed ID: 18339818
    [No Abstract]   [Full Text] [Related]  

  • 108. Cervical screening uptake in a dermatology cohort on immunosuppressive agents.
    Clowry J; Callanan I; Eustace K; Collins P; Kirby B; Lally A
    Br J Dermatol; 2015 Jun; 172(6):1682-1683. PubMed ID: 25495166
    [No Abstract]   [Full Text] [Related]  

  • 109. Re: An alternative cost-effectiveness analysis of ThinPrep in the Australian setting.
    Llewellyn H
    Aust N Z J Obstet Gynaecol; 2006 Feb; 46(1):67. PubMed ID: 16441702
    [No Abstract]   [Full Text] [Related]  

  • 110. Uterine cervical neoplasia prevention in Parque Indigena do Xingu.
    Speck NM; Pereira ER; Schaper M; Tso FK; de Freitas VG; Ribalta JC
    Eur J Gynaecol Oncol; 2009; 30(4):415-7. PubMed ID: 19761134
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Cervical cancer: what every woman needs to know.
    Nursing; 2003 Nov; Suppl():11-2. PubMed ID: 14748154
    [No Abstract]   [Full Text] [Related]  

  • 112. Strategies to maximise cervical cancer screening rates among older Hong Kong Chinese women--a cultural consensus analysis study.
    Shiu AT; Twinn SF; Lee GC; Chan CW; Kwong KK
    J Clin Nurs; 2010 Nov; 19(21-22):3244-6. PubMed ID: 21040026
    [No Abstract]   [Full Text] [Related]  

  • 113. Generalised cost-effectiveness analysis for breast cancer prevention and care in Hong Kong Chinese.
    Wong IO; Tsang JW; Cowling BJ; Leung GM
    Hong Kong Med J; 2015 Dec; 21 Suppl 6():9-12. PubMed ID: 26645875
    [No Abstract]   [Full Text] [Related]  

  • 114. Cervical Cancer: The Next Generation of Prevention, Detection, and Treatment.
    Duska LR
    Clin Ther; 2016 Mar; 38(3):446-8. PubMed ID: 26993033
    [No Abstract]   [Full Text] [Related]  

  • 115. Development and evaluation of a multimedia intervention to promote cervical cancer prevention among South Asian women in Hong Kong.
    So WKW; Law BMH; Chan CWH; Leung DYP; Chan HYL; Chair SY
    Ethn Health; 2022 Feb; 27(2):284-296. PubMed ID: 31701760
    [No Abstract]   [Full Text] [Related]  

  • 116. Evaluation of the new cervical cancer screening program in Georgia.
    Mirzikashvili N; Beruchashvili T; McNutt LA
    Int J Gynaecol Obstet; 2012 Jun; 117(3):288-9. PubMed ID: 22425010
    [No Abstract]   [Full Text] [Related]  

  • 117. Limitations of simulation models for cervical cancer screening - Authors' reply.
    Malagón T; Kulasingam S; Franco EL
    Lancet Oncol; 2019 Feb; 20(2):e69. PubMed ID: 30712802
    [No Abstract]   [Full Text] [Related]  

  • 118. Cervical screening among Chinese females in the era of HPV vaccination: a population-based survey on screening uptake and regular screening following an 18-year organized screening program.
    Choi HC; Leung K; Wu JT
    J Gynecol Oncol; 2024 Mar; 35(2):e20. PubMed ID: 37921604
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
    Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
    BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis.
    Choi HCW; Jit M; Leung GM; Tsui KL; Wu JT
    BMC Med; 2018 Aug; 16(1):127. PubMed ID: 30115065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.